BioSpace News Archive

Akero Therapeutics, Inc., a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis, reported second quarter financial results for the period ending June 30, 2021.

A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast tracked and is now published in the renowned peer-reviewed scientific publication The Lancet Oncology1.

The American Association of Kidney Patients (AAKP) thanks the U.S. Food and Drug Administration (FDA) for incorporating the unique insights of America’s kidney transplant recipients and the medical professionals who care for them in their authorization of a third vaccine dose.

Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the geographical expansion of the PRIMAvera European pivotal trial in atrophic dry age-related macular degeneration with the opening of the first clinical site in the UK at the Moorfields Eye Hospital in London.

The increasing investments to implement digital technologies in the medical industry, the evolution of connected care, and the growing adoption of wearable devices are boosting growth in the IoT medical devices market.

Transparency Market Research has published a new report on the home blood pressure monitoring devices market for the forecast period of 2019–2027.

The increasing geriatric population and rising chronic diseases require intensive care from health professionals.

The diabetic neuropathy market study by Fact.MR offers compelling insights into key growth drivers and restraints impacting the market through 2031.

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that it received comments from the U.S. Food and Drug Administration on the Company’s recently submitted dose justification report, an important component to the Company’s resubmission of its Biologics License Application for HIV.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced its financial results and operational highlights for the quarter ended June 30, 2021.